At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 34 enrolled
Drug / intervention
Oral Vancomycindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
In Brief
A Phase 3 clinical trial evaluating Oral Vancomycin for Primary Sclerosing Cholangitis. Completed, enrolled 34 participants across 1 site.
Detailed Summary
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Sclerosing Cholangitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2012
First PostedMar 2013
Primary CompletionAug 2015
TodayJul 2026
First PostedMar 1, 2013
Enrollment StartJan 1, 2012
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 13.3 years ago
Interventions
Oral Vancomycindrug